Venetoclax Combinations Approved for Older Patients with AML

The U.S. Food and Drug Administration (FDA) approved a novel targeted drug to treat acute myelogenous leukemia (AML) in older patients, a segment of the blood cancer population in dire need of improved therapies. In a phase 3 clinical trial, researchers showed that the oral drug, venetoclax (or Venclexta), when given along with azacitidine, could … Continued

Patient Living Life Despite Leukemia and COVID-19

Tim O’Neill likes to keep moving — whether on his boat, his motorcycle, in his running shoes, or while steering an RV across 47 states. Chronic lymphocytic leukemia (CLL) has failed to stop him from these pursuits, and he’s determined not to let a pandemic do so either. “I’m more careful these days because of … Continued

New Drug Regimens Show Promise in Early and Late Myeloma

Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Continued

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results … Continued

Cancer Patient Faces Multiple Diagnoses with the Strength of a Warrior

One bout of cancer is enough to contend with, but since 2014 Mary Johnson has had to cope with four different cancers and related conditions. Despite these tests of her physical and emotional strength, Johnson is doing well today after treatment at Dana-Farber. “Coming to Dana-Farber gave me confidence because they supported me, and I … Continued

‘Watchful Waiting’ for Lymphoma: What You Need to Know

If you’ve been diagnosed with slow-growing lymphoma but don’t have any symptoms of the disease, your doctor is likely to recommend monitoring the disease closely but not treating it until symptoms appear — an approach known as watchful waiting. This advice might seem to run counter to the standard recommendation that cancer be treated at … Continued

Approval of Myeloma Drug Improves Patients’ Prospects

Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Continued

Transplant Program Milestone is Patient’s First Step in Returning to the Dance Floor

The first time Bill Cronin Googled his own cancer diagnosis in 2016, his heart sank. He had Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma  — and staring back at him were countless articles predicting a negative prognosis. However, after receiving a stem-cell transplant at Dana-Farber/Brigham and Women’s Cancer Center, Cronin is … Continued

Patient and Author with Multiple Myeloma is Writing His Own Next Chapter

For many years, Thomas Palayoor and his wife, Sanjeewani, were engaged in cancer research in India. Inspired by the revolutionary advances being made in the biomedical field in the United States, they decided to move to the U.S. in 1978. Working at the medical schools of Ohio State University and Yale University, Palayoor branched off … Continued

Immunotherapy for Blood Cancers: What’s New?

Immunotherapy for cancer has made some of its biggest inroads against hematologic malignancies such as leukemia and lymphoma, with treatments such as checkpoint inhibitors and CAR T-cell therapies producing long-lasting remissions in some patients. But there’s broad agreement that the potential of such therapies has only begun to be tapped and that combining immunotherapy drugs … Continued

What is Mantle Cell Lymphoma and How Is It Treated?

Mantle cell lymphoma is a rare, often aggressive form of non-Hodgkin lymphoma (NHL), a cancer that involves white blood cells known as lymphocytes, which help protect the body from disease. It is named for its origins in the mantle zone — a ring of cells within the lymph nodes where B cells (a type of … Continued

Multiple Myeloma Fails to Keep Football Player-Turned-Broadcaster Out of Action

Many sports stars have helped support research and care at Dana-Farber by appearing on the WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance Foundation, but few have done so quite like pro football wide receiver-turned-broadcaster Jimmy Cefalo. When Cefalo was interviewed on-air during the August 2019 event at Fenway Park, he used the opportunity to share some … Continued

What Are the Differences Between Lymphocytic and Myelogenous Leukemia?

Medically reviewed by Martha Wadleigh, MD Leukemia arises from malfunctions in stem cells within the bone marrow that cause abnormal white blood cells to flood into the bloodstream. Leukemias are classified as either myelogenous (also called myeloid) or lymphocytic, depending on which types of white blood cells are affected. What is the difference between these types … Continued

Adult Leukemia: What You Need to Know

More than 60,000 new cases of adult leukemia are diagnosed in the U.S. each year. Although it is one of the more common childhood cancers, leukemia occurs more often in older adults. How does leukemia develop in adults? Leukemia is a cancer of the body’s blood-forming tissues that results in large numbers of abnormal or immature white blood … Continued

What Are the Most Common Blood Cancers in Adults?

The most commonly diagnosed blood cancers are non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and multiple myeloma. Here’s what you need to know about each type of cancer. Non-Hodgkin lymphoma Non-Hodgkin lymphoma (NHL) is a type of cancer that forms in the lymph system, part of the body’s immune system. There … Continued

New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies

Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. A clinical trial found that 26.2 percent of such patients responded with significant shrinkage … Continued